**YM      BIOSCIENCES INC.**

**WORK      ORDER**

**A      Phase II Open-Label, 2-Cohort Study ofNimotuzumab 400 mg Weekly plus**

**Irinotecan      (Cohort 1) and Nimotuzumab 400 mg Every 2 weeks plus Irinotecan (Cohort      2) in Patients with Irinotecan-Refractory Metastatic Colorectal      Cancer**

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**Table      of Contents**

----

| 1.                Proposal Details                           | 3  |
|--------------------------------------------------------------|----|
| 2.                Corporate Summary                          | 4  |
| Features                & Benefits                       | 4  |
| Team                & Location                           | 5  |
| Technology                                                   | 5  |
| Standards                                                    | 5  |
| Corporate                & Clinical Organizational Chart | 7  |
| Services                                                     | 8  |
| *Project                Management*                          | 8  |
| *Regulatory                Affairs*                          | 8  |
| *Clinical                Monitoring*                         | 8  |
| *Operational                Support*                         | 9  |
| *Medical                Writing*                             | 9  |
| *Quality                Assurance*                           | 10 |
| *Data                Management*                             | 10 |
| *Training*                                                   | 11 |
| *Clinical                Supply Logistics*                   | 11 |
| *Affiliate                Services*                          | 11 |
| 3.                Therapeutic Experience                     | 12 |
| 4.                ProjectTeam                                | 14 |
| Project                Oversight                             | 14 |
| Project                Management                            | 15 |
| Clinical                Research Associates                  | 15 |
| Clinical                Operations Associates                | 16 |
| Quality                Assurance                             | 16 |
| 5.                Project Summary                            | 17 |
| Project                Timelines                             | 21 |
| Roles                and Rates                               | 21 |
| Project                Details                               | 22 |
| 6.                Estimate                                   | 36 |
| 7.                Pass-Through Cost Estimate                 | 38 |
| 8.                Payment Schedule and Terms                 | 40 |
| 9.                Standard Practices                         | 40 |
| 10.                Client Signatures                         | 41 |
| 11.                Letter of Intent                          | 42 |

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**1.      Proposal Details**

----

| **Title:**                             | A                Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly                plus                Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks plus Irinotecan                (Cohort 2) in Patients with Irinotecan-Refractory Metastatic Colorectal                Cancer                                                                                                                                                                                                                                                                                                           |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Protocol                #:**         | YMB1000-015                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Customer:**                          | YM                BioSciences Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **MSA#:**                              | YMBO7-MSA-30APR2007-                1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Proposal                No.:**       | YMBO7-WOI-29MAR2007-2.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Customer                Reference:** | YMBO7-WO1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Confidentiality:**                   | Restricted –                Commercial Copyright and Reproduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                   | This                proposal is submitted by Allphase Clinical Research Inc. in response                to                the invitation issued by Ms. Nancy Cohen, Project Manager at YM                BioSciences Inc. dated 28FEB2007, with revisions requested on 12& 30                MAR; 01 APR2007. It may not be used for any other purposes, reproduced                in                whole or in part, nor passed to any organization or person without                the                specific permission in writing of the President, Allphase Clinical                Research Services Inc. |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Proposal                Date:**      | 02APR2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Version:**                           | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **Validity:**                          | 90                days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| **CRO                Address:**        | Allphase                Clinical Research Services Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                   | 19                Camelot Drive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                   | Ottawa,                ON Canada K2G 5W6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                   | P:                (613) 228-1990                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                   | F:                (613) 228-8493                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                   | C:                (613) 291-2362                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                   | Email:                jsmith@allphaseclinical.com                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

| **Approved                by:** |                        |   |                     |
|---------------------------------|-----------------------------|--------|--------------------------|
|                            | /s/              Jeff Smith |   | 22              May 2007 |
|                            | Jeff                Smith   |   | Date                     |
|                            | President                   |   |                     |

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**2.      Corporate Summary**

----

***Helping      You Improve LifeTM***

***Features      & Benefits***

|   | t | Established                  policies, practices, and standards to maximize client value and                  ensure                  client confidentiality; |
|--------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | t | Experienced                      personnel with a solid foundation in clinical trial management,                      a                      disciplined work ethic, and an emphasis on customer                      service; |
|--------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | t | Access                  to premier clinical research sites and therapeutic experts across                  North                  America; |
|--------|---|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | t | A                  personable, team-focused approach;                  and |
|--------|---|----------------------------------------------------------------------------|

|   | t | Innovative,                  time-saving technologies. |
|--------|---|--------------------------------------------------------|

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**Allphase      Clinical Research is an ideal-sized organization to provide the most value      to      our clients.**

***Team      & Location***

***Technology***

***Standards***

|  | t | Standard                  Operating Procedures and                  policies; |
|--|---|-------------------------------------------------------------------------------|

|  | t | Monitored,                  state-of-the-art security                  systems; |
|--|---|---------------------------------------------------------------------------------|

|  | t | Access-controlled                facility; |
|--|---|--------------------------------------------|

|  | t | Access-controlled                and independently alarmed clinical supply                room; |
|--|---|-------------------------------------------------------------------------------------------------|

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

|  | t | Access-controlled                Trial Master File room; |
|--|---|----------------------------------------------------------|

|  | t | Access-controlled                secure server room; |
|--|---|------------------------------------------------------|

|  | t | Appropriate                data storage and redundancy                systems; |
|--|---|--------------------------------------------------------------------------------|

|  | t | Robust                anti-virus and firewall security; |
|--|---|---------------------------------------------------------|

|  | t | 128-bit                VPN encryption; |
|--|---|----------------------------------------|

|  | t | VoIP                communications system; |
|--|---|--------------------------------------------|

|  | t | Teleconferencing                capability; and |
|--|---|-------------------------------------------------|

|  | t | Proprietary                data/document processing systems. |
|--|---|--------------------------------------------------------------|

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**Corporate      & Clinical Organizational Chart**

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**Services**

***Project      Management***

|  | t | IND/CTA                maintenance; |
|--|---|-------------------------------------|

|  | t | Collaborative                interaction with regulatory authorities and                IRBs; |
|--|---|-----------------------------------------------------------------------------------------------|

|  | t | Investigator                site selection and feasibility                assessments; |
|--|---|----------------------------------------------------------------------------------------|

|  | t | Regulatory                document package design (site                level); |
|--|---|--------------------------------------------------------------------------------|

|  | t | Contract                and budget preparation, negotiation, and                administration; |
|--|---|-------------------------------------------------------------------------------------------------|

|  | t | Investigator                meeting organization and site                training; |
|--|---|------------------------------------------------------------------------------------|

|  | t | CRA                resourcing, mentoring, and co-monitoring                support; |
|--|---|-------------------------------------------------------------------------------------|

|  | t | Monitoring                report review; |
|--|---|------------------------------------------|

|  | t | SAE                reporting coordination; |
|--|---|--------------------------------------------|

|  | t | Coordination                of site/ vendor/ client communications;                and |
|--|---|----------------------------------------------------------------------------------------|

|  | t | Managing                client expectations for on-time and on-budget                performance. |
|--|---|---------------------------------------------------------------------------------------------------|

***Regulatory      Affairs***

|  | t | Investigational                New Drug Applications (INDs); |
|--|---|--------------------------------------------------------------|

|  | t | New                Drug Applications (NDAs); |
|--|---|----------------------------------------------|

|  | t | Abbreviated                New Drug Applications (NDAs); |
|--|---|----------------------------------------------------------|

|  | t | Biologic                License Applications (BLAs); |
|--|---|------------------------------------------------------|

|  | t | New                Drug Submissions (NDSs); |
|--|---|---------------------------------------------|

|  | t | Abbreviated                New Drug Submissions (ANDSs); |
|--|---|----------------------------------------------------------|

|  | t | Clinical                Trial Applications (CTAs). |
|--|---|----------------------------------------------------|

***Clinical      Monitoring***

|  | t | Site                initiation, routine monitoring, and                close-out; |
|--|---|-----------------------------------------------------------------------------------|

|  | t | Site                personnel training, mentoring, and                guidance; |
|--|---|---------------------------------------------------------------------------------|

|  | t | Assessing                protocol compliance and data                integrity; |
|--|---|---------------------------------------------------------------------------------|

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

|  | t | Regulatory                document review; |
|--|---|--------------------------------------------|

|  | t | Pharmacy                training and drug accountability;                and |
|--|---|------------------------------------------------------------------------------|

|  | t | Ensuring                  GCP, consenting, confidentiality, and safety requirements are                  met. |
|--|---|---------------------------------------------------------------------------------------------------------------|

***Operational      Support***

***Medical      Writing***

|  | t | Phase                I-IV study protocols; |
|--|---|--------------------------------------------|

|  | t | Investigational                drug brochures; |
|--|---|------------------------------------------------|

|  | t | Informed                consent forms; |
|--|---|----------------------------------------|

|  | t | Case                report form and diary card design; |
|--|---|--------------------------------------------------------|

|  | t | Clinical                study reports and safety                narratives; |
|--|---|-----------------------------------------------------------------------------|

|  | t | Presentation                posters and PowerPoint                Presentations; |
|--|---|----------------------------------------------------------------------------------|

|  | t | Technical                briefs; and |
|--|---|--------------------------------------|

|  | t | Training                manuals. |
|--|---|----------------------------------|

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

***Quality      Assurance***

**objective assessment **

|  | t | Evaluation                and auditing of GCP quality                processes: |
|--|---|---------------------------------------------------------------------------------|

|  | o | Vendor                qualification and due diligence audits (CROs, central IRBs, clinical/                diagnostic laboratories, centralized ECG/PFT readers, clinical data                management, clinical supplies                distributors); |
|--|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | o | Clinical                investigator site audits; |
|--|---|---------------------------------------------------|

|  | o | Clinical                data management process audits; |
|--|---|---------------------------------------------------------|

|  | o | Clinical                study report and regulatory submission document                audits; |
|--|---|------------------------------------------------------------------------------------------------|

|  | o | Systems                audits (pharmacovigilance and drug safety reporting, computer system                validation documentation compliance, clinical research                operations). |
|--|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | t | Standard                Operating Procedure (SOP) and policies                development: |
|--|---|--------------------------------------------------------------------------------------------|

|  | o | Clinical                research SOP gap analyses and needs                assessment; |
|--|---|----------------------------------------------------------------------------------------|

|  | o | Facilitation                of SOP/policies development, approval process, distribution and training                activities; |
|--|---|---------------------------------------------------------------------------------------------------------------------------------|

|  | o | Collaborative                design and writing of customized SOPs and                policies. |
|--|---|-------------------------------------------------------------------------------------------------|

***Data      Management***

|  | t | CRF                and database design; |
|--|---|-----------------------------------------|

|  | t | AE                and medical coding and reporting; |
|--|---|-----------------------------------------------------|

|  | t | Clinical                trial safety database/                reconciliation; |
|--|---|-------------------------------------------------------------------------------|

|  | t | Lab                data import; |
|--|---|---------------------------------|

|  | t | Single                and double data entry; |
|--|---|----------------------------------------------|

|  | t | Query                generation; |
|--|---|----------------------------------|

|  | t | Data                validation, storage and archiving;                and |
|--|---|---------------------------------------------------------------------------|

|  | t | Biostatistics. |
|--|---|----------------|

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

***Training***

**The      Allphase Center of Excellence (ACE)**

***Clinical      Supply Logistics***

***Affiliate      Services***

|  | t | Statistical                Analysis; |
|--|---|--------------------------------------|

|  | t | Medical                Monitoring; |
|--|---|------------------------------------|

|  | t | DSMB. |
|--|---|-------|

***Our      Team is Your Team***

**full-time      employees**

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**3.      Therapeutic Experience**

----

| **Therapeutic                  Area** |   | **#                  of studies** |   | **Indications**                                                                                                                                                          |
|---------------------------------------|--------|-----------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Allergy/ Respiratory             |   | 7                                 |   | AsthmaChronic                  Obstructive Pulmonary DiseasePerennial                  Allergic RhinitisSeasonal                  Allergic Rhinitis                      |
| Cardiovascular                        |   | 9                                 |   | Atrial                  FibrillationDeep                  Vein ThrombosisIntermittent                  ClaudicationPulmonary                  Embolism                   |
| CNS                                   |   | 6                                 |   | Amyotrophic                  Lateral SclerosisAlzheimer’s                  Disease DepressionMultiple                  SclerosisSmoking                  Cessation |
| Endocrinology                         |   | 5                                 |   | DiabetesDyslipidemia                                                                                                                                                     |
| Infectious                  Disease   |   | 6                                 |   | HepatitisHIV                                                                                                                                                             |
| Oncology                              |   | 8                                 |   | BrainBreastHead                  and Neck Ovarian                  Renal                  Cell CarcinomaSmall                  Cell Lung                                 |
| Other                                 |   | 8                                 |   | Alpha-1                  Antitrypsin DeficiencyChronic                  Idiopathic UrticariaImmunodeficiencyPrimary                  Immune DeficiencyRabies             |
| **TOTAL**                             |   | **49**                            |   |                                                                                                                                                                     |

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**Oncology      Experience**

| **Therapeutic                  Area**            | ** ** | **Phase** | ** ** | **#                  of Sites** | ** ** | **#                  of Subjects** |
|--------------------------------------------------|------------|-----------|------------|---------------------------------|------------|------------------------------------|
|                                             |       |      |       |                            |       |                               |
| Small                  Cell Lung Cancer          |       | I/Il      |       | 5                               |       | 48                                 |
|                                             |       |      |       |                            |       |                               |
| Advanced                  Breast Cancer          |       | II        |       | 5                               |       | 30                                 |
|                                             |       |      |       |                            |       |                               |
| Metastatic                  Renal Cell Carcinoma |       | II        |       | 1                               |       | 5                                  |
|                                             |       |      |       |                            |       |                               |
| Metastatic                  Breast Cancer        |       | II        |       | 4                               |       | 37                                 |
|                                             |       |      |       |                            |       |                               |
| Squamous                  Cell Carcinoma         |       | II        |       | 6                               |       | 20                                 |
|                                             |       |      |       |                            |       |                               |
| Squamous                  Cell Carcinoma         |       | II        |       | 6                               |       | 10                                 |
|                                             |       |      |       |                            |       |                               |
| Pediatric                  Brain Tumors          |       | I         |       | 1                               |       |  19                           |
|                                             |       |      |       |                            |       |                               |
| Ovarian                  Cancer                  |       | II        |       | 7                               |       | 40                                 |

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

**4.      Project Team**

----

**Project      Oversight**

***Thelma      Spencer, BScH: Director of Clinical Operations (Ottawa)***

***Sue      Boyd, RN: Manager, Allphase Center of Excellence; CRA Manager      (Ottawa)***

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**Project      Management**

***Wendy      Kirby, RN: Project Manager (Ottawa)***

| **#                  of****Studies** | ** ** | **Phase** | ** ** | **Indication**                          |
|--------------------------------------|------------|-----------|------------|-----------------------------------------|
| 2                                    |       | III       |       | Metastatic                  Colorectal  |
| 1                                    |       | II/III    |       | Ovarian                  Cancer         |
| 3                                    |       | III       |       | Cervical                  Dystonia      |
| 1                                    |       | I         |       | Hemifacial                  Spasm       |
| I                                    |       | III       |       | International                  Melanoma |
| 1                                    |       | III       |       | AML                                     |

| **Therapy                  Area**    | ** ** | **Indication**                                                                                                                                                    |
|--------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hematology                           |       | Chemotherapy                  administration: AML, Hodgkin’s Disease, NHL and apharesis                  administration                                     |
| Infectious                  Diseases |       | Antiviral                  research: HIV                                                                                                                          |
| Oncology                             |       | Breast,                  Ovarian, Acute Myeloid Leukemia, Colorectal, NSCL, SCL, Melanoma,                  Hodgkin’s Disease, Non Hodgkin’s Lymphoma |
| Neurological                         |       | Alzheimer’s                  Disease, Cervical Dystonia                                                                                                     |

**Clinical      Research Associates**

***Karry      Schenk (Ottawa, ON) ***

***Faye      Aspelund (Ottawa, ON) ***

----

----

| **MSA#:**                        | YMBO7-MSA-30APR2007-1.0 | **WO                Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

***Isabelle      Keeley, REN (Ottawa, ON) ***

***Moira      MacDonald, RN (Toronto, ON) ***

***Andrea      Murphy, RN (Vancouver, BC) ***

**Clinical      Operations Associates**

***Alison      Conley; Litharitza Vakopoulos; Ewa Lifsches (Ottawa, ON) -***

**Quality      Assurance**

***Linda      Kraft, RN, Quality Assurance Auditor (Ottawa, ON)***

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**5.        Project Summary**

----

| **Protocol**                 |   |                                                                                                                                                                                                                                                                                                                                                                                                     |
|------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Drug                         |   | Nimotuzumab                  (TheraCIM®,                  YMB 1000, h-R3)                                                                                                                                                                                                                                                                                                                           |
| Indication                   |   | Metastatic                  Colorectal Cancer                                                                                                                                                                                                                                                                                                                                                            |
| Phase                        |   | II                                                                                                                                                                                                                                                                                                                                                                                                       |
| Title                        |   | A                  Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly                  plus                  Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks plus                  Irinotecan                  (Cohort 2) in Patients with Irinotecan-Refractory Metastatic Colorectal                  Cancer                                                                  |
| Short                  Title |   | Nimotuzumab                  plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal                  Cancer                                                                                                                                                                                                                                                                                      |
| Objectives                   |   | **Primary:**To                  evaluate whether the combination of Irinotecan and nimotuzumab                  will result                  in a lower incidence of Grade 2 or greater acneform rash or infusion                  reaction, allergic reaction or anaphylactoid reaction AEs in patients                  with                  irinotecan-refractory metastatic colorectal cancer. |
|                         |   | **Secondary:**•                  To evaluate whether the combination of irinotecan and one of the                  2                  different dosing schedules of nimotuzumab will result in an objective                  response rate (ORR) in patients with irinotecan-refractory metastatic                  colorectal cancer.                                                             |
|                         |   | •                  To compare progression-free survival (PFS), defined as time from                  date of                  randomization until date of disease progression (clinical or radiological)                  or death due to any cause, in each nimotuzumab                  arm;                                                                                                     |

----

----

| **MSA#:**                              | YMBO7-MSA-30APR2007-1.0 | **WO                      Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|----------------------------------------|-------------------------|-------------------------------------------|-------------------------|
| **Version                      Date:** | 02APR2007               | **Work                      Order #:**    | 01                      |

|                                                           |             | •                        To compare the rate and duration of Stable Disease (SD) in                        each treatment                        arm;                                                                                                                                      |
|----------------------------------------------------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                           |             | •                        To compare the time to disease progression (TTP) in each                        treatment                        arm;                                                                                                                                             |
|                                                           |             | •                        To compare ORR in patients who are identified as having “primary”                        irinotecan resistance according to stratification criteria                        at the time of                        randomization in each treatment arm; |
|                                                           |             | •                        To compare overall survival in each tx arm;                                                                                                                                                                                                                       |
|                                                           |             | •                        To compare the overall safety and toxicity profiles of 2                        dose regimens of                        nimotuzumab plus irinotecan;                                                                                                              |
|                                                           |             | •                        To compare incidence of symptomatic rash, defined as any                        rash or pain in                        each treatment arm,                                                                                                                        |
|                                                           |             | •                        To define the biologically effective dose of                                                                                                                                                                                                                      |
|                                                           |             | nimotuzumab                        based on ORR and safety data                                                                                                                                                                                                                                  |
|                                                           |             | which                        can serve as a reference for future studies.                                                                                                                                                                                                                        |
| **Sites**                                                      |             |                                                                                                                                                                                                                                                                                             |
| No.                        of Investigator Meetings            | 1                |                                                                                                                                                                                                                                                                                             |
| Investigator                        Meeting Location           |             | TBD                                                                                                                                                                                                                                                                                              |
| Number                        of Treatment Groups              | 2                |                                                                                                                                                                                                                                                                                             |
| Local                        of Central IRB                    |             | Local                                                                                                                                                                                                                                                                                            |
| Number                        of Sites                         | [*]              |                                                                                                                                                                                                                                                                                             |
| Location                        of sites                       |             | [*]                                                                                                                                                                                                                                                                                              |
| Number                        of Site Selection Visits         | 0                |                                                                                                                                                                                                                                                                                             |
| Number                        of Initiation Visits             | 11               |                                                                                                                                                                                                                                                                                             |
| Est.                        # of Monitoring hrs/ SF CRF        | 0.5              | assuming                        minimal data review & collection                                                                                                                                                                                                                             |
| Est.                        # of Monitoring hrs/ Completed CRF | 16               | Based                        on 60 CRF pages per patient. Also includes: query resolution                        (monitoring                        & DM generated); drug accountability; proportional share of                        regulatory                        reconciliation      |
| Estimated                        Number of Monitoring Hour     |  1605  |                                                                                                                                                                                                                                                                                             |
| Estimated                        Number of Monitoring Days     | 229              | 7                        hour monitoring day (1hr for site administration)                                                                                                                                                                                                                       |
| Estimated                        Number of Visits per Site     | 21               | assumes                        1 day visit                                                                                                                                                                                                                                                       |
| Estimated                        Monitoring Frequency          | 6                | every                        6 weeks (1 day visits)                                                                                                                                                                                                                                              |
| Estimated                        Number of Monitors            | 3                | Workload                        estimated at 1.3 FTE. 3 CRAs regionally distributed will                        save travel                        costs.                                                                                                                                        |
| Estimated                        Number of Close-out Visits    | 11               |                                                                                                                                                                                                                                                                                             |
| Estimated                        Number of Ad-Hoc Visits       | 4                | PM                        visits to YMB (approx every 6 months)                                                                                                                                                                                                                                  |
| Estimated                        Number of Co-Visits by PM     | 3                |                                                                                                                                                                                                                                                                                             |

----

----

| **MSA#:**                        | YMB07-MSA-30APR2007-l.0 | **WO                Version Code:** | YMB07-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

| **Subjects**                                                  |   |                                                                  |
|---------------------------------------------------------------|--------|-----------------------------------------------------------------------|
| Number                  of Subjects Screened                  | 110    |                                                                  |
| Number                  of Subjects Randomized                | 100    |                                                                  |
| Enrolment                  Period                             | 78     | weeks                  (FPFV 06/2007 to LPFV 12/2008)                 |
| Duration                  of Each Subject                     | 26     | weeks                  (Scr; 26 wk Tx)                                |
| Follow                  Up of Each Subject                    | 26     | Weeks(26                  wk FU)                                      |
| Total                  Study Duration (all subjects - active) | 104    | weeks                  (FPFV 06/2007 to LPLV (active period) 06/2009) |
| Total                  Study Duration (all subjects)          | 130    | weeks                  (30 mo)                                        |
| Total                  Study Duration (PM) Active Period      | 104    | weeks                                                                 |
| Total                  Study Duration (PM) Follow-Up Period   | 26     | weeks                                                                 |
| Total                  Study Duration (PM)                    | 138    | weeks                  (total study duration + 8 weeks F/U)           |
| Estimated                  # PM hours/week (active period)    | 11     | hours                  (1hr/wk/site)                                  |
| Estimated                  # PM hours/week (F/U period)       | 5.5    | hours                  (0.5hr/wk/site)                                |
| Estimated                  Number of SAE                      | 100    |                                                                  |
| **Medical                  Writing**                          |   |                                                                  |
| Number                  of Medical Reports                    | 1      |                                                                  |
| **SOP**                                                       |   |                                                                  |
| SOPs                  to be used                              |   | YM                  BioSciences                                       |
| Forms                                                         |   | YM                  BioSciences                                       |
| **Data                  Management**                          |   |                                                                  |
| Allphase                  DM                                  |   | paper                  CRF                                            |
| **Quality                  Assurance**                        |   |                                                                  |
| Site                  Audits                                  | 4      |                                                                  |
| Vendor                  Audits                                | 2      | Central                  lab for PK samples & Radiology Lab       |
| QA                  Audit of Clinical Database                | 0      |                                                                  |
| QA                  Audit of Clinical Study Report            | 0      |                                                                  |
| QA                  Audit of Study File                       | 0      |                                                                  |
| **Vendors**                                                   |   |                                                                  |
| Number                  of Laboratories                       |   | Local                  & Central (PK)                             |
| Investigational                  Product Distributor          |   | YM                  BioSciences                                       |
| Radiology                  Review                             | 120    | based                  on 20% responders and 6 images/patient         |
| **Services                  Requested**                       |   |                                                                  |
|                                                          | N/A    | **Regulatory**                                                        |
|                                                          |   | CTA                  prep, submission and maintenance                 |
|                                                          |   | **Project                  Management**                               |

----

----

| **MSA#:**                        | YMB07-MSA-30APR2007-l.0 | **WO                Version Code:** | YMB07-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

|   | N/A    | Site                  Contract Negotiation and Payment Facilitation |
|--------|--------|---------------------------------------------------------------------|
|   |   |                                                                |
|   | N/A    | Regulatory                  Document Collection                     |
|   |   |                                                                |
|   | N/A    | ICF                  Preparation & Translation                  |
|   |   |                                                                |
|   | N/A    | IRB                  preparations and submissions - central         |
|   |   | IRB;                  or assistance with the submissions if         |
|   |   | local                  IRB.                                         |
|   |   |                                                                |
|   | N/A    | Site                  Identification                                |
|   |   | Multi-site                  Management                              |
|   |   | CRA                  Management                                     |
|   |   | Teleconference                  and Project Updates                 |
|   |   | Vendor                  Management (if applicable)                  |
|   |   | General                  Administration                             |
|   |   |                                                                |
|   |   | **Investigator                  Meeting**                           |
|   |   | Planning                  & Execution                           |
|   |   | Presentations                                                       |
|   |   | Travel                  Arrangements for Attendees                  |
|   |   |                                                                |
|   |   | **Clinical                  Monitoring**                            |
|   | N/A    | Pre-Study                  Visits                                   |
|   |   | Site                  Initiation                                    |
|   |   | Interim                  Monitoring & site management           |
|   |   | Site                  Close Out                                     |
|   |   |                                                                |
|   |   | **Safety**                                                          |
|   |   | Safety                  Database                                    |
|   |   | CIOMS/                  MedWatch report prep                        |
|   |   | SAE                  alert reporting to authorities                 |
|   |   |                                                                |
|   |   | **Data                  Management/Biostatistics**                  |
|   |   | CRF                  Design & build                             |
|   |   | DM                  System Set Up (include edit checks)             |
|   |   | Data                  Validation and Review CRFs                    |
|   |   | Data                  Query                                         |
|   |   | Coding                  AE & Medications                        |
|   |   | Interim                  Analysis Plan                              |
|   |   | Final                  Analysis Plan                                |

----

----

| **MSA#:**                        | YMB07-MSA-30APR2007-l.0 | **WO                Version Code:** | YMB07-WO1-29MAR2007-2.3 |
|----------------------------------|-------------------------|-------------------------------------|-------------------------|
| **Version                Date:** | 02APR2007               | **Work                Order #:**    | 01                      |

|   |   | **Medical                Monitoring**                  |
|--------|--------|--------------------------------------------------------|
|   |   |                                                   |
|   |   | **Radiology                Review**                    |
|   |   |                                                   |
|   |   | **Medical                Writing**                     |
|   |   | Draft                & Final Clinical Study Report |
|   |   |                                                   |
|   |   | **Quality                Assurance**                   |
|   |   | GCP                Investigator/Site/ Vendor Audit     |
|   | N/A    | QA                Audit of Clinical Database           |
|   | N/A    | QA                Audit of Clinical Study Report       |

**Project      Timelines**

| **Activity**                                              |   | **Date                  of Completion** |
|-----------------------------------------------------------|--------|-----------------------------------------|
| Contract                  or LOI executed                 |   | Apr-07                                  |
| Investigator                  Meeting                     |   | Apr-Jun-07                              |
| First                  patient enrolled                   |   | Jun-07                                  |
| 25%                  subjects enrolled                    |   | Nov-07                                  |
| 50%                  subjects enrolled                    |   | Mar-07                                  |
| 75%                  subjects enrolled                    |   | Aug-08                                  |
| Enrollment                  completed                     |   | Dec-08                                  |
| Last                  patient/ last visit (active period) |   | Jun-09                                  |
| Database                  Lock                            |   | Aug-09                                  |
| Final                  close out visit                    |   | Oct-09                                  |

**Roles      and Rates**

| **Allphase Role** |   | **Allphase                  Resource**         |   | **Hourly                  Rate** |
|------------------------|--------|------------------------------------------------|--------|----------------------------------|
| DE                     |   | Data                  Entry Personnel          |   | $                                | [*] |
| COA                    |   | Clinical                  Operations Associate |   | $                                | [*] |
| CRA                    |   | Clinical                  Research Associate   |   | $                                | [*] |
| DM                     |   | Data                  Manager                  |   | $                                | [*] |
| MW                     |   | Medical                  Writing               |   | $                                | [*] |
| PM                     |   | Project                  Manager               |   | $                                | [*] |
| RA                     |   | Regulatory                  Affairs            |   | $                                | [*] |
| DS                     |   | Drug                  Safety                   |   | $                                | [*] |
| QA                     |   | Quality                  Assurance Auditor     |   | $                                | [*] |
| BlO                    |   | Biostatistician                                |   | $                                | [*] |
| ACE                    |   | Trainer                                        |   | $                                | [*] |
| MM                     |   | Medical                  Monitor               |   | $                                | [*] |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**Project      Details**

| x   |   | Full                Responsibility                   |
|-----|--------|------------------------------------------------------|
| (x) |   | Partial                Responsibility/ Input/ Advice |
| ADM |   | Data                Management                       |

| **List                  of Tasks**                                                                                |       | **YM**     |       | **Allphase** |       | **ADM**    |       | **Task****Hours** |       | **Units**  |       | **Total****Hours** |       | **Resp** |
|-------------------------------------------------------------------------------------------------------------------|------------|------------|------------|--------------|------------|------------|------------|-------------------|------------|------------|------------|--------------------|------------|----------|
| **Pre-Study                  Activities**                                                                         |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Project                  Feasibility study                                                                        |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Protocol                Development                                                                          |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Synopsis                                                                                                          |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Draft                                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Review                                                                                                            |       | x          |       | (x)          |       |       |       | 8                 |       | 1          |       | 8                  |       | PM       |
| Final                                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Protocol                  Amendments                                                                              |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| Draft                                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Review                                                                                                            |       | x          |       | (x)          |       |       |       | 4                 |       | 1          |       | 4                  |       | PM       |
| Final                                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Compilation                  & update IB                                                                      |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| Draft                                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Review                                                                                                            |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Final                                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
| Paper                  CRF Preparation                                                                            |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| Draft                                                                                                             |       | n/a        |       |         |       |       |       |              |       |       |       |               |       |     |
| Review                                                                                                            |       | n/a        |       |         |       |       |       |              |       |       |       |               |       |     |
| Final                                                                                                             |       | n/a        |       |         |       |       |       |              |       |       |       |               |       |     |
| Printing                                                                                                          |       | n/a        |       |         |       |       |       |              |       |       |       |               |       |     |
| CRF                  Design (CA3)                                                                                 |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| CRF                  Design - Draft (17 unique forms, 60CRF                  pages/pt) - template provided by YMB |       |       |       | x            |       |       |       | 40                |       | 1          |       | 40                 |       | PM       |
| CRF                  Draft Review & Revisions                                                                 |       | (x)        |       | x            |       |       |       | 16                |       | 1          |       | 16                 |       | CRA      |
| Edit                  Check Development                                                                           |       |       |       | x            |       |       |       | 8                 |       | 1          |       | 8                  |       | PM       |
| Review                  & Finalize Programmed Edit Checks                                                     |       |       |       | x            |       |       |       | 8                 |       | 1          |       | 8                  |       | PM       |
| Final                  Review and Final Revisions to CRF                                                          |       | (x)        |       | x            |       |       |       | 16                |       | 1          |       | 16                 |       | PM       |
| CRF                  Completion Guidelines (revisions incl)                                                       |       |       |       | x            |       |       |       | 36                |       | 1          |       | 36                 |       | PM       |
| CRF                  Completion Guidelines - review                                                               |       |       |       | x            |       |       |       | 8                 |       | 1          |       | 8                  |       | CRA      |
| CRF                  printing logistics and QC                                                                    |       |       |       | x            |       |       |       | 4                 |       | 1          |       | 4                  |       | PM       |
| Project                  Plan                                                                                     |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| SOPs                  assignment documentation                                                                    |       | (x)        |       | x            |       |       |       | 3                 |       | 1          |       | 3                  |       | PM       |
| Responsibility                  assignment                                                                        |       | (x)        |       | x            |       |       |       | 3                 |       | 1          |       | 3                  |       | PM       |
|                                                                                                              |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| **Total**                                                                                                         |       |       |       |         |       |       |       |              |       |       |       | **24**             | ** ** | **CRA**  |
| ** **                                                                                                        | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **130**            | ** ** | **PM**   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                                                               |   | **YM** |   | **Allphase** |   | **ADM** |   | **Task****Hours** |   | **Units**    |   | **Total****Hours** |       | **Resp**     |
|------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------------|--------|---------|--------|-------------------|--------|--------------|--------|--------------------|------------|--------------|
| **Submissions                  to FDA**                                                                          |   | n/a    |   |         |   |    |   |              |   |         |   |               |       |         |
| US                  agent                                                                                        |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| amendment                  & maintenance                                                                     |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| **CTA                  - Health Canada**                                                                         |   | x      |   |         |   |    |   |              |   |         |   |               |       |         |
| Canadian                  Agent                                                                                  |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| Preparation                  & Submission                                                                    |   |   |   |         |   |    |   | 0                 |   | 0            |   | 0                  |       | RA           |
| Clarifax                  response                                                                               |   |   |   |         |   |    |   | 0                 |   | 0            |   | 0                  |       | RA           |
| Review                  of Approval NOL & follow-up                                                          |   |   |   |         |   |    |   | 0                 |   | 0            |   | 0                  |       | RA           |
| Submission                  of CTSI forms to TPD                                                                 |   |   |   |         |   |    |   | 0                 |   | 0            |   | 0                  |       | RA           |
| amendment                  & maintenance                                                                     |   |   |   |         |   |    |   | 0                 |   | 0            |   | 0                  |       | RA           |
|                                                                                                             |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| **Total**                                                                                                        |   |   |   |         |   |    |   |              |   |         |   | **0**              | ** ** | **RA**       |
|                                                                                                             |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| **Vendors**                                                                                                      |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| ID                  & contracting lab                                                                        |   |   |   | x            |   |    |   | 12                |   | 1            |   | 12                 |       | PM           |
| ID                  & contracting Radiology Review                                                           |   |   |   | x            |   |    |   | 12                |   | 1            |   | 12                 |       | PM           |
| Vendor                  Assessment                                                                               |   |   |   | x            |   |    |   |              |   |         |   |               |       |         |
| Provide                  sites with manual                                                                       |   | n/a    |   |         |   |    |   |              |   |         |   |               |       |         |
| Payment                  administration & tracking                                                           |   |   |   | x            |   |    |   | 8                 |   | 1            |   | 8                  |       | PM           |
|                                                                                                             |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| **Total**                                                                                                        |   |   |   |         |   |    |   |              |   |         |   | **32**             | ** ** | **PM**       |
| **Investigator’s                  Meeting**                                                                |   |   |   |         |   |    |   |              |   |         |   |               |       |         |
| Identify                  location and conduct preliminary investigation of costs;                  reservations |   | x      |   | (x)          |   |    |   | 8                 |   | 1            |   | 8                  |       | COA          |
| Organize                  travel & hotel for study team                                                      |   |   |   | x            |   |    |   | 14                |   | 1            |   | 14                 |       | COA          |
| Plan                  and organize IM                                                                            |   |   |   | x            |   |    |   | 24                |   | 1            |   | 24                 |       | PM           |
| Prepare                  agenda                                                                                  |   | (x)    |   | x            |   |    |   | 3                 |   | 1            |   | 3                  |       | PM           |
| Prepare                  presentations                                                                           |   | x      |   | x            |   |    |   | 8                 |   | 1            |   | 8                  |       | PM           |
| Design                  Investigator Meeting materials                                                           |   | x      |   | x            |   |    |   | 8                 |   | 1            |   | 8                  |       | PM           |
| Prepare                  Investigator Meeting materials                                                          |   | x      |   | x            |   |    |   | 16                |   | 1            |   | 16                 |       | COA          |
| Prepare                  welcome letters, name tags, meeting materials                                           |   | x      |   | x            |   |    |   | 12                |   | 1            |   | 12                 |       | COA          |
| Ensure                  vendor/sponsor presentations are organized and appropriate                               |   | x      |   | x            |   |    |   | 8                 |   | 1            |   | 8                  |       | PM           |
| Attendance                  and presentations at Investigator meeting                                            |   | x      |   | x            |   | x       |   |              |   |         |   |               |       |         |
|                                                                                                             |   |   |   |         |   |    |   |         |   |    |   |          |       |    |
| PM                  prep                                                                                         |   |   |   |         |   |    |   | 2                 |   | 1            |   | 2                  |       | PM           |
| PM                  travel                                                                                       |   |   |   |         |   |    |   | 16                |   | 1            |   | 16                 |       | PM           |
| PM                  presentation & attendance                                                                |   |   |   |         |   |    |   | 16                |   | 1            |   | 16                 |       | PM           |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                          |       | **YM**     |       | **Allphase** |       | **ADM**    |       | **Task****Hours** |       | **Units**  |       | **Total****Hours** |       | **Resp** |
|-------------------------------------------------------------|------------|------------|------------|--------------|------------|------------|------------|-------------------|------------|------------|------------|--------------------|------------|----------|
| CRA                  prep                                   |       |       |       |         |       |       |       | 2                 |       | 3          |       | 6                  |       | CRA      |
| CRA                  travel                                 |       |       |       |         |       |       |       | 16                |       | 3          |       | 48                 |       | CRA      |
| CRA                  attendance                             |       |       |       |         |       |       |       | 16                |       | 3          |       | 48                 |       | CRA      |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| ACE                  Trainer prep                           |       |       |       |         |       |       |       | 2                 |       | 0          |       | 0                  |       | ACE      |
| ACE                  Trainer travel                         |       |       |       |         |       |       |       | 16                |       | 0          |       | 0                  |       | ACE      |
| ACE                  Trainer presentation & attendance  |       |       |       |         |       |       |       | 8                 |       | 0          |       | 0                  |       | ACE      |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| COA                  prep                                   |       |       |       |         |       |       |       | 2                 |       | 1          |       | 2                  |       | COA      |
| COA                  travel                                 |       |       |       |         |       |       |       | 16                |       | 1          |       | 16                 |       | COA      |
| COA                  attendance                             |       |       |       |         |       |       |       | 16                |       | 1          |       | 16                 |       | COA      |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| DM                  prep                                    |       |       |       |         |       |       |       | 2                 |       | 0          |       | 0                  |       | DM       |
| DM                  travel                                  |       |       |       |         |       |       |       | 16                |       | 0          |       | 0                  |       | DM       |
| DM                  presentation & attendance           |       |       |       |         |       |       |       | 8                 |       | 0          |       | 0                  |       | DM       |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| MM                  prep                                    |       |       |       |         |       |       |       | 2                 |       | 1          |       | 2                  |       | MM       |
| MM                  travel                                  |       |       |       |         |       |       |       | 16                |       | 1          |       | 16                 |       | MM       |
| MM                  presentation & attendance           |       |       |       |         |       |       |       | 8                 |       | 1          |       | 8                  |       | MM       |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| **Sub-Total                  - PM**                         | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **85**             | ** ** | **PM**   |
| **Sub-Total                  - CRA**                        | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **102**            | ** ** | **CRA**  |
| **Sub-Total                  - ACE**                        | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **0**              | ** ** | **ACE**  |
| **Sub-Total                  - COA**                        | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **84**             | ** ** | **COA**  |
| **Sub-Total                  - DM**                         | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **0**              | ** ** | **DM**   |
| **Sub-Total                  - MM**                         | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **26**             | ** ** | **MM**   |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| **Ethics**                                                  |       |       |       |         |       |       |       |              |       |       |       |               |       |     |
| Preparation                  of ICF template (PIPEDA)       |       | x          |       |         |       |       |       | 16                |       | 0          |       | 0                  |       | PM       |
| Customization                  of ICF (PIPEDA)              |       | n/a        |       |         |       |       |       | 8                 |       | 0          |       | 0                  |       | PM       |
| Preparation                  of other subject materials     |       | x          |       |         |       |       |       | 12                |       | 0          |       | 0                  |       | PM       |
| Assist                  sites with submissions              |       | x          |       |         |       |       |       | 3                 |       | 0          |       | 0                  |       | PM       |
| IRB                  approval review & action if needed |       | x          |       |         |       |       |       | 2                 |       | 0          |       | 0                  |       | PM       |
| Translation                  of ICF & materials         |       | x          |       |         |       |       |       | 6                 |       | 0          |       | 0                  |       | PM       |
| Subsequent                  ICF revisions (amendments)      |       | x          |       |         |       |       |       | 8                 |       | 0          |       | 0                  |       | PM       |
| IND                  Safety alert reporting to sites        |       | x          |       |         |       |       |       | 2                 |       | 0          |       | 0                  |       | PM       |
| Annaul                  re-approval documentation           |       | x          |       |         |       |       |       | 4                 |       | 0          |       | 0                  |       | PM       |
| Study/                  site closure documentation          |       | x          |       |         |       |       |       | 4                 |       | 0          |       | 0                  |       | PM       |
| IRB                  payment facilitation                   |       | x          |       |         |       |       |       | 1                 |       | 0          |       | 0                  |       | PM       |
| IRB                  payment                                |       | x          |       |         |       |       |       |              |       |       |       |               |       |     |
|                                                        |       |       |       |         |       |       |       |              |       |       |       |               | ** ** |     |
| **Total**                                                   |       |       |       |         |       |       |       |              |       |       |       | **0**              |       | **PM**   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                    of Tasks**                                              |   | **YM** |   | **Allphase** |   | **ADM** |   | **Task****Hours** |       | **Units** |       | **Total****Hours** |   | **Resp** |
|-----------------------------------------------------------------------------------|--------|--------|--------|--------------|--------|---------|--------|-------------------|------------|-----------|------------|--------------------|--------|----------|
| **CRA**                                                                           |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| **Site                    Selection Visits**                                      |   | x      |   |         |   |    |   |              |       |      |       |               |   |     |
| Contact                    sites and confirm date for visit                       |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Send                    confirmation letter                                       |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Interview                    PI and site staff regarding experience               |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    project requirements and expectations                   |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Tour                    facility and assess site                                  |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Prepare                    report and make recommendation of site suitability     |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Prep                                                                              |   |   |   |         |   |    |   | 1                 |       | 0         |       | 0                  |   | CRA      |
| Travel                                                                            |   |   |   |         |   |    |   | 8                 |       | 0         |       | 0                  |   | CRA      |
| On-Site                                                                           |   |   |   |         |   |    |   | 3                 |       | 0         |       | 0                  |   | CRA      |
| Admin                                                                             |   |   |   |         |   |    |   | 4                 |       | 0         |       | 0                  |   | CRA      |
|                                                                              |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Sub-Total/site                                                                    |   |   |   |         |   |    |   |              |       |      |       | 0                  |   | CRA      |
| **Total**                                                                         |   |   |   |         |   |    |   | **0**             | ** ** | **0**     | ** ** | **0**              |   | **CRA**  |
|                                                                              |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| **Site                    Initiation Visit**                                      |   |   |   | x            |   |    |   |              |       |      |       |               |   |     |
| Contact                    sites and confirm date for visit and provide an agenda |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Send                    confirmation letter                                       |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Complete                    Monitors’ Sign-In Log                           |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    regulatory documentation                                |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    Study protocol and CRF including:                       |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Inclusion                    /exclusion criteria                                  |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Efficacy                    parameters and measurement                            |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Study                    schedule                                                 |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Complete/evaluable                    patient definitions                         |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Study                    medication procedures                                    |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Lab                    requirements                                               |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| CRF                    completion instructions                                    |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    adverse event reporting, including:                     |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Definition                    of AEs and SAEs.                                    |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Requirements                    for documentation collection                      |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Proper                    procedures for reporting SAEs to Sponsor and REB.       |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Follow-up                    requirements                                         |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    Investigational Brochure                                |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    communication channels                                  |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| Review                    requirements for source documentation                   |   |   |   |         |   |    |   |              |       |      |       |               |   |     |
| IRB/site                    responsibilities                                      |   |   |   |         |   |    |   |              |       |      |       |               |   |     |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                                                                                    |   | **YM** |   | **Allphase** |   | **ADM** |   | **Task****Hours** |       | **Units** |       | **Total****Hours** |       | **Resp** |
|---------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------------|--------|---------|--------|-------------------|------------|-----------|------------|--------------------|------------|----------|
| Review                  monitoring schedule                                                                                           |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Review                  study site documentation                                                                                      |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Train                  study coordinators                                                                                             |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Review                  PI contract and payment schedule                                                                              |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Prepare                  study initiation visit report                                                                                |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Send                  site SIV report and ackg. form                                                                                  |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Prep                                                                                                                                  |   |   |   |         |   |    |   | 2                 |       | 1         |       | 2                  |       | CRA      |
| Travel                                                                                                                                |   |   |   |         |   |    |   | 8                 |       | 1         |       | 8                  |       | CRA      |
| On-Site                                                                                                                               |   |   |   |         |   |    |   | 5                 |       | 1         |       | 5                  |       | CRA      |
| Admin                                                                                                                                 |   |   |   |         |   |    |   | 4                 |       | 1         |       | 4                  |       | CRA      |
|                                                                                                                                  |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Sub-Total/site                                                                                                                        |   |   |   |         |   |    |   | 19                |       | 1         |       | 19                 |       | CRA      |
| **Total**                                                                                                                             |   |   |   |         |   |    |   | **19**            | ** ** | **11**    | ** ** | **209**            | ** ** | **CRA**  |
|                                                                                                                                  |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Interim                  Monitoring**                                                                                               |   |   |   | x            |   |    |   |              |       |      |       |               |       |     |
| Send                  confirmation letter                                                                                             |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Complete                  Monitors’ Sign-In Log                                                                                 |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Verify                  proper Informed Consent procedures                                                                            |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Montior                  in accordance with protocol/ICH/GCP                                                                          |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| 100%                  source document verification vs CRF                                                                             |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Assess                  patient eligibility (protocol inclusion / exclusion / randomization                  criteria)                |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Provide                  site with written query records to be retained with each                  CRF                                |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Review                  study-related regulatory documents                                                                            |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Review                  monitoring & discrepancy report queries                                                                   |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Source                  verify data clarfication/ correction forms                                                                    |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Review                  of laboratory data                                                                                            |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Review                  and verify SAEs (100% SDV)                                                                                    |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Verify                  study drug inventory and storage                                                                              |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Verify                  proper accountability and destruction of IP and study supplies                  per                  protocol |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Maintain                  protocol violation list                                                                                     |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Monitoring                  of other variables as specified                                                                           |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Prepare                  monitoring visit reports following each monitoring visit                                                     |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Provide                  monitoring follow-up reports to sites following each visit                                                   |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Regular                  contacts with sites & TC reports                                                                         |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Ongoing                  training of site personnel                                                                                   |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| CRF                  and query management                                                                                             |   |   |   |         |   |    |   |              |       |      |       |               |       |     |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                                                                                  |       | **YM**     |       | **Allphase** |       | **ADM**    |       | **Task****Hours** |       | **Units**  |       | **Total****Hours** |       | **Resp**   |
|-------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|--------------|------------|------------|------------|-------------------|------------|------------|------------|--------------------|------------|------------|
| Prep                                                                                                                                |       |       |       |         |       |       |       | 1                 |       | 1          |       | 1                  |       | CRA        |
| Travel                                                                                                                              |       |       |       |         |       |       |       | 6                 |       | 1          |       | 6                  |       | CRA        |
| On-Site                                                                                                                             |       |       |       |         |       |       |       | 8                 |       | 1          |       | 8                  |       | CRA        |
| Admin                                                                                                                               |       |       |       |         |       |       |       | 5                 |       | 1          |       | 5                  |       | CRA        |
|                                                                                                                                |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Sub-Total/site                                                                                                                      |       |       |       |         |       |       |       | 20                |       | 1          |       | 20                 |       | CRA        |
| **Total**                                                                                                                           |       |       |       |         |       |       |       | **20**            | ** ** | **229**    | ** ** | **4580**           | ** ** | **CRA**    |
|                                                                                                                                |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| **Close                  Out Visit**                                                                                                |       |       |       | x            |       |       |       |              |       |       |       |               |       |       |
| COV                  within 6 weeks post data base lock                                                                             |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Contact                  potential sites, confirm date for visit                                                                    |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Send                  confirmation letter                                                                                           |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Complete                  Monitors’ Sign-In Log                                                                               |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Ensure                  site regulatory documentation is complete and accessible for future                  audits                 |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Ensure                  that the investigator is aware of his/her responsibilities                                                  |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Ensure                  that any remaining clinical trial material is removed from the                  study                  site |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Prepare                  COV report following visit                                                                                 |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Provide                  follow-up report to sites                                                                                  |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Follow-up                  with sites to resolve open issues                                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Prep                                                                                                                                |       |       |       |         |       |       |       | 1                 |       | 1          |       | 1                  |       | CRA        |
| Travel                                                                                                                              |       |       |       |         |       |       |       | 8                 |       | 1          |       | 8                  |       | CRA        |
| On-Site                                                                                                                             |       |       |       |         |       |       |       | 8                 |       | 1          |       | 8                  |       | CRA        |
| Admin                                                                                                                               |       |       |       |         |       |       |       | 5                 |       | 1          |       | 5                  |       | CRA        |
|                                                                                                                                |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Sub-Total/site                                                                                                                      |       |       |       |         |       |       |       | 22                |       | 1          |       | 22                 |       | CRA        |
| **Total**                                                                                                                           |       |       |       |         |       |       |       | **22**            | ** ** | **11**     | ** ** | **242**            | ** ** | **CRA**    |
| ** **                                                                                                                          | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | ** **         | ** ** | ** ** |
| **CRA                  Total**                                                                                                      | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **5031**           | ** ** | **CRA**    |
|                                                                                                                                |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| **Overall                  Project Management**                                                                                     |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| **In-house                  study management**                                                                                      |       |       |       |         |       |       |       |              |       |       |       |               |       |       |
| Selection                  - US sites                                                                                               |       | N/A        |       |         |       |       |       |              |       |       |       |               |       |       |
| Selection                  - CDN site                                                                                               |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |
| Identification                  & contracting of vendors                                                                        |       | N/A        |       |         |       |       |       |              |       |       |       |               |       |       |
| Feasibility                  form admin (incl. initial contact)                                                                     |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |
| Confidential                  Discl. Agreement - template                                                                           |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |
| CDA                  Approval                                                                                                       |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |
| CTRA                  template                                                                                                      |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |
| CTRA                  template approval                                                                                             |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |
| CTRA                  negotiation                                                                                                   |       | x          |       |         |       |       |       |              |       |       |       |               |       |       |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                                                  |   | **YM** |   | **Allphase** |   | **ADM** |   | **Task****Hours** |   | **Units** |   | **Total****Hours** |   | **Resp** |
|-----------------------------------------------------------------------------------------------------|--------|--------|--------|--------------|--------|---------|--------|-------------------|--------|-----------|--------|--------------------|--------|----------|
| CTRA                  - site sign off                                                               |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
|                                                                                                |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| Preparation                  of initial project specific reg pkg                                    |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Review                  received reg docs:                                                          |   | x      |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| site                  - 1572                                                                        |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| site                  - QIU                                                                         |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| REBA                                                                                                |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| CTSI                                                                                                |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| Consent                  to Use Personal Data                                                       |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| Protocol                  signature page                                                            |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| IB                  distribution to sites                                                           |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| Financial                  Disclosure                                                               |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| CV                                                                                                  |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| biosketch                                                                                           |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| MD                  qualification                                                                   |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| lab                  ref ranges & license                                                       |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
|                                                                                                |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| Internal                  monthly project team meetings                                             |   |   |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Site                  level management                                                              |   |   |   | x            |   |    |   |              |   |      |   |               |   |     |
| Regular                  status reports for client                                                  |   |   |   | x            |   |    |   |              |   |      |   |               |   |     |
| Liaise                  bi-weekly with sponsor                                                      |   |   |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| TMF                  Set-up & Maintenance                                                       |   |   |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Track                  CRF completion & queries and manage deficiencies                         |   |   |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Site                  budget set-up                                                                 |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Payment                  calculation                                                                |   |   |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Payment                  tracking                                                                   |   | x      |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Payment                  issuance                                                                   |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
|  Preparation                  of Project Plan                                                  |   | (x)    |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Preparation                  of Monitoring Plan                                                     |   | (x)    |   | x            |   |    |   |              |   |      |   |               |   | PM       |
| Prep.                  of initiation Visit Booklet                                                  |   | (x)    |   | x            |   |    |   |              |   |      |   |               |   | PM       |
|                                                                                           |   |   |   |         |   |    |   |              |   |      |   |               |   |     |
| **Prep.                  of Study specific forms**                                                  |   | x      |   |         |   |    |   |              |   |      |   |               |   | PM       |
| Prep.                  study specific tracking tools                                                |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| CRF                  Transmittal Logs                                                               |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| QoL,                  questionnaires and/or patient diaries, patient (alert)                  cards |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Drug                  Accountability Form                                                           |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Individual                  Subject Drug logs                                                       |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Drug                  Return & Reconciliation Form                                              |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Clinical                  Re-Supplies Form                                                          |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Drug                  Receipt Form                                                                  |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |
| Release                  of IP (RIP) Form                                                           |   | x      |   |         |   |    |   |              |   |      |   |               |   |     |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                                                          |   | **YM** |   | **Allphase** |   | **ADM** |   | **Task****Hours** |       | **Units** |       | **Total****Hours** |       | **Resp** |
|-------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------------|--------|---------|--------|-------------------|------------|-----------|------------|--------------------|------------|----------|
| Destruction                  of IP (DIP) Form                                                               |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
|  Study                  specific tracking tools                                                        |   | (x)    |   | x            |   |    |   |              |       |      |       |               |       | PM       |
|                                                                                                        |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Investigational                Product (IP) and other Clinical Study Supplies**                           |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Labeling,                  coding and packing of IP (including provision of sample                  labels) |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Identification                  of Drug Distribution Vendor                                                 |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Comparator                  Procurement                                                                     |   | N/A    |   |         |   |    |   |              |       |      |       |               |       |     |
| Preparation                  of written instructions for handling and storage of IP                         |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Request                  for import/export approvals for IP                                                 |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Preparation                  of custom clearance(s)                                                         |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Storage                  of IP                                                                              |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Development/maintenance                  Randomization System/Codes                                         |   |   |   | x            |   |    |   |              |       |      |       |               |       | DM       |
| Request                  for authorization to release IP to sites                                           |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Authorization                  to distribute drug                                                           |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Packaging/labeling                  of Clinical Supplies                                                    |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Distribution                  of Clinical Study Supplies to sites                                           |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Tracking                  of IP                                                                             |   | x      |   | x            |   |    |   |              |       |      |       |               |       | PM       |
| Tracking                  of Clinical Study Supplies                                                        |   | x      |   | x            |   |    |   |              |       |      |       |               |       | PM       |
| Organization                  of return of unused Clinical Study Supplies                                   |   |   |   | x            |   |    |   |              |       |      |       |               |       | CRA      |
| Organization                  of destruction of unused Clinical Study Supplies                              |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
|                                                                                                        |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Study                  Completion/Study Termination**                                                     |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| Notification                  to national/local authorities of study termination                            |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
| Final                  recon of TMF                                                                         |   |   |   | x            |   |    |   |              |       |      |       |               |       | PM       |
| Archiving                  of Sponsor’s TMF                                                           |   | x      |   |         |   |    |   |              |       |      |       |               |       |     |
|                                                                                                        |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Sub-Total                  (est. hours/ week x # wks)****Active                  Period**                 |   |   |   | x            |   |    |   | **11**            | ** ** | **104**   | ** ** | **1144**           | ** ** | **PM**   |
|                                                                                                        |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Sub-Total                  (est. hours/week x # wks)****Follow-Up                  Period**               |   |   |   | x            |   |    |   | **5.5**           | ** ** | **26**    | ** ** | **143**            | ** ** | **PM**   |
|                                                                                                        |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Ex-house                  Project Management**                                                            |   |   |   |         |   |    |   |              |       |      |       |               |       |     |
| **Site                  Selection Visits**                                                                  |   |   |   | x            |   |    |   |              |       |      |       |               |       |     |
| Prep                                                                                                        |   |   |   |         |   |    |   | 2                 |       | 0         |       | 0                  |       | PM       |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                |   | **YM**       |   | **Allphase** |   | **ADM**      |   | **Task****Hours** |       | **Units** |       | **Total****Hours** |       | **Resp** |
|-------------------------------------------------------------------|--------|--------------|--------|--------------|--------|--------------|--------|-------------------|------------|-----------|------------|--------------------|------------|----------|
| Travel                                                            |   |         |   |         |   |         |   | 14                |       | 0         |       | 0                  |       | PM       |
| On-Site                                                           |   |    |   |    |   |    |   | 3                 |       | 0         |       | 0                  |       | PM       |
| Admin                                                             |   |         |   |         |   |         |   | 5                 |       | 0         |       | 0                  |       | PM       |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| Sub-Total/site                                                    |   |         |   |         |   |         |   |              |       |      |       |               |       | PM       |
| **Total**                                                         |   |         |   |         |   |         |   | **0**             | ** ** | **0**     | ** ** | **0**              | ** ** | **PM**   |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| **Co-Initiation/Monitoring/COV**                                  |   |         |   | x            |   |         |   |              |       |      |       |               |       |     |
| Prep                                                              |   |         |   |         |   |         |   | 1                 |       | 1         |       | 1                  |       | PM       |
| Travel                                                            |   |         |   |         |   |         |   | 8                 |       | 1         |       | 8                  |       | PM       |
| On-Site                  (average)                                |   |         |   |         |   |         |   | 8                 |       | 1         |       | 8                  |       | PM       |
| Admin                                                             |   |         |   |         |   |         |   | 1                 |       | 1         |       | 1                  |       | PM       |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| Sub-Total/site                                                    |   |         |   |         |   |         |   |              |       |      |       | 18                 |       | PM       |
| **Total**                                                         |   |         |   |         |   |         |   | **18**            |       | **3**     |       | **54**             |       | **PM**   |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| **Ad                  hoc meetings (4 trips)**                    |   |         |   | x            |   |         |   |              |       |      |       |               |       |     |
| Prep                                                              |   |         |   |         |   |         |   | 1                 |       | 1         |       | 1                  |       | PM       |
| Travel                                                            |   |         |   |         |   |         |   | 6                 |       | 1         |       | 6                  |       | PM       |
| On-Site                  (average)                                |   |         |   |         |   |         |   | 8                 |       | 1         |       | 8                  |       | PM       |
| Admin                                                             |   |         |   |         |   |         |   | 3                 |       | 1         |       | 8                  |       | PM       |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| Sub-Total/site                                                    |   |         |   |         |   |         |   |              |       |      |       |  18           |       | PM       |
| **Total**                                                         |   |         |   |         |   |         |   | **18**            |       | **4**     |       | **72**             |       | **PM**   |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| **Total**                                                         |   |         |   |         |   |         |   |              |       |      |       | **1413**           |       | **PM**   |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| **Administration                  - COA**                         |   |         |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Assemble                  site reg. packages                      |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Courier                  packages to sites                        |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Receive,                  log, scan & file initial reg docs   |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Follow-up                  on reg doc errors & omissions      |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Courier                  - second round                           |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Receive,                  log, scan & file 2nd round reg docs |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
|                                                              |   |         |   |         |   |         |   |              |       |      |       |               |       |     |
| Assemble                  PI Site Files (ISF) for TMF             |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Courier                  site ISF to PI                           |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| Assemble                  TMF                                     |   |         |   | x            |   |         |   | 16                |       | 1         |       | 16                 |       | COA      |
| Assemble                  In-House site File (IHF) for TMF        |   |         |   | x            |   |         |   | 3                 |       | 11        |       | 33                 |       | COA      |
| CRF                  related admin                                |   |         |   | x            |   |         |   | 16                |       | 1         |       | 16                 |       | COA      |
| CDA                  - send to sites; review; send to Client      |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |
| CTRA                  - send to sites; review; send to Client     |   | x            |   |         |   |         |   | 0                 |       | 0         |       | 0                  |       | COA      |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                  of Tasks**                                |   | **YM** |   | **Allphase** |   | **ADM** |   | **Task****Hours** |   | **Units** |   | **Total****Hours** |       | **Resp** |
|-------------------------------------------------------------------|--------|--------|--------|--------------|--------|---------|--------|-------------------|--------|-----------|--------|--------------------|------------|----------|
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **COA                  Pre-Study Total**                          |   |   |   |         |   |    |   |              |   |      |   | **65**             | ** ** | **COA**  |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **General                  Admin**                                |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| Post                  tracking tools to web for client            |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| Assist                  with IRB/ reg. authority submissions      |   | x      |   |         |   |    |   |              |   |      |   |               |       |     |
| Ongoing                  regulatory doc. tracking/ scanning       |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| Trial                  Master File maintenance                    |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| Contact                  sites for enrolment updates              |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| High                  level site support                          |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| Assist                  with query resolution                     |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| TC                  minutes                                       |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
| Return                  of Sponsor’s TMF                    |   |   |   | x            |   |    |   |              |   |      |   |               |       |     |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **COA                  General Admin (Active) Total**             |   |   |   |         |   |    |   | 5                 |   | 104       |   | 520                |       | COA      |
| **COA                  General Admin (Follow-up) Total**          |   |   |   |         |   |    |   | 3                 |   | 34        |   | 102                |       | COA      |
| **Total**                                                         |   |   |   |         |   |    |   |              |   |      |   | **622**            | ** ** | **COA**  |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **Allphase                  Center of Excellence (ACE) Training** |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| Site                  level GCP/ICH CRF training                  |   |   |   | n/a          |   |    |   |              |   |      |   |               |       |     |
| Source                  documentation                             |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| Drug                  accountability                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| DM                  insight for reducing queries                  |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| ACE                  Trainer prep                                 |   |   |   |         |   |    |   | 0                 |   | 0         |   | 0                  |       | ACE      |
| ACE                  Trainer travel                               |   |   |   |         |   |    |   | 0                 |   | 0         |   | 0                  |       | ACE      |
| ACE                  Trainer attendance                           |   |   |   |         |   |    |   | 0                 |   | 0         |   | 0                  |       | ACE      |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **Total**                                                         |   |   |   |         |   |    |   |              |   |      |   | 0                  | ** ** | **ACE**  |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **Medical                  Writing**                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| Review                  of therapeutic area/medication            |   | x      |   |         |   |    |   |              |   |      |   |               |       |     |
| Review                  of protocol/related study documents       |   | x      |   |         |   |    |   |              |   |      |   |               |       |     |
| Integration                  of tables/statistical analysis plan  |   | x      |   |         |   |    |   |              |   |      |   |               |       |     |
| Preparation                  of draft report #1                   |   | (x)    |   | x            |   |    |   | 60                |   | 1         |   | 60                 |       | MW       |
| Preparation                  of draft report #2                   |   | (x)    |   | x            |   |    |   | 40                |   | 1         |   | 40                 |       | MW       |
| Preparation                  of draft report #3                   |   | (x)    |   | x            |   |    |   | 30                |   | 1         |   | 30                 |       | MW       |
| Preparation                  of final report                      |   | (x)    |   | x            |   |    |   | 30                |   | 1         |   | 30                 |       | MW       |
|                                                              |   |   |   |         |   |    |   |              |   |      |   |               |       |     |
| **Total**                                                         |   |   |   |         |   |    |   |              |   |      |   | **160**            | ** ** | **MW**   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                of Tasks**                                               | ** ** | **YM** | ** ** | **Allphase** | ** ** | **ADM** | ** ** | **Task****Hours** | ** ** | **Units** | ** ** | **Total****Hours** | ** ** | **Resp** |   |
|--------------------------------------------------------------------------------|------------|--------|------------|--------------|------------|---------|------------|-------------------|------------|-----------|------------|--------------------|------------|----------|--------|
| Quality                Assurance                                               |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| Familiarization                with client SOPs (if applicable)                |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Familiarization                with protocol                                   |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Inspection                of site regulatory files                             |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Review                and assessment of site SOPs                              |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Random                sampling of source and CRF data                          |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Discussion                with site personnel re: processes and findings.      |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Inspection                of client TMF regulatory files                       |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Review                of vendor facilities, SOPs, processes                    |       |   |       | N/A          |       |    |       |              |       |      |       |               |       |     |   |
| Discussion                with vendor personnel re: processes and findings.    |       |   |       | N/A          |       |    |       |              |       |      |       |               |       |     |   |
| Preparation                of audit report                                     |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Follow-up                of resolutions                                        |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
|                                                                           |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| **Vendor                Audits**                                               |       |   |       | N/A          |       |    |       |              |       |      |       |               |       |     |   |
| Prep                                                                           |       |   |       |         |       |    |       | 6                 |       |      |       |               |       |     |   |
| Travel                                                                         |       |   |       |         |       |    |       | 6                 |       |      |       |               |       |     |   |
| On-Site                                                                        |       |   |       |         |       |    |       | 8                 |       |      |       |               |       |     |   |
| Report                Writing                                                  |       |   |       |         |       |    |       | 6                 |       |      |       |               |       |     |   |
| **Sub-Total**                                                                  |       |   |       |         |       |    |       | **26**            |       | **2**     |       | **52**             |       | **QA**   |   |
| **Site                Audits** (ü(n+1))                                   |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Prep                                                                           |       |   |       |         |       |    |       | 8                 |       |      |       |               |       |     |   |
| Travel                                                                         |       |   |       |         |       |    |       | 8                 |       |      |       |               |       |     |   |
| On-Site                                                                        |       |   |       |         |       |    |       | 16                |       |      |       |               |       |     |   |
| Report                Writing                                                  |       |   |       |         |       |    |       | 8                 |       |      |       |               |       |     |   |
| **Sub-Total**                                                                  |       |   |       |         |       |    |       | **40**            |       | **4**     |       | **160**            |       | **QA**   |   |
| **TMF                Audit**                                                   |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Prep                                                                           |       |   |       |         |       |    |       | 2                 |       |      |       |               |       |     |   |
| Travel                                                                         |       |   |       |         |       |    |       | 0                 |       |      |       |               |       |     |   |
| On-Site                                                                        |       |   |       |         |       |    |       | 16                |       |      |       |               |       |     |   |
| Report                Writing                                                  |       |   |       |         |       |    |       | 8                 |       |      |       |               |       |     |   |
| **Sub-Total**                                                                  |       |   |       |         |       |    |       | **26**            |       | **0**     |       | **0**              |       | **QA**   |   |
|                                                                           |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| **Total**                                                                      |       |   |       |         |       |    |       |              |       |      |       | **212**            |       | **QA**   |   |
|                                                                           |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| **Safety**                                                                     |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| **Overall                Medical Oversight**                                   |       | (x)    |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Manage                site questions                                           |       |   |       | x            |       |    |       | 0.5               |       | 110       |       | 55                 |       | MM       |   |
| review                patient eligibility                                      |       |   |       | x            |       |    |       | 0.5               |       | 110       |       | 55                 |       | MM       |   |
| Protocol                deviation decision making and management (as required) |       | (x)    |       | x            |       |    |       | 0.75              |       | 100       |       | 75                 |       | MM       |   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                of Tasks**                                                                                           | ** ** | **YM**     | ** ** | **Allphase** | ** ** | **ADM**    | ** ** | **Task****Hours** | ** ** | **Units**  | ** ** | **Total****Hours** | ** ** | **Resp** |       |
|----------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|--------------|------------|------------|------------|-------------------|------------|------------|------------|--------------------|------------|----------|------------|
| SAE                Trend Analysis                                                                                          |       |       |       | x            |       |       |       | 8                 |       | 2          |       | 16                 |       | MM       |       |
| Protocol                deviation processing and tracking                                                                  |       |       |       | x            |       |       |       | 0.75              |       | 100        |       | 75                 |       | PM       |       |
| **AE/SAE                Database Setup**                                                                                   |       |       |       | x            |       |       |       |              |       |       |       |               |       |     |       |
| AE/SAE                Coding and Reporting                                                                                 |       |       |       |         |       | x          |       |              |       |       |       |               |       | DM       |       |
| Medications                Coding                                                                                          |       |       |       |         |       | x          |       |              |       |       |       |               |       | DM       |       |
| **SAE                Collection, Processing & Reporting**                                                              |       |       |       | x            |       |       |       |              |       |       |       |               |       |     |       |
| SAE                report receipt, processing & follow-up                                                              |       |       |       | x            |       |       |       | 1                 |       | 100        |       | 100                | ** ** | DS       |       |
| Submit                Alert Reports to Reg. Agencies/ IRB/ Sponsor                                                         |       |       |       | x            |       |       |       | 0.75              |       | 100        |       | 75                 | ** ** | DS       |       |
| Submit                SAE Reports to Sites                                                                                 |       |       |       | x            |       |       |       | 0.75              |       | 100        |       | 75                 | ** ** | PM       |       |
| **SAE                Evaluation**                                                                                          |       |       |       | x            |       |       |       | 0.5               |       | 100        |       | 50                 | ** ** | MM       |       |
| **24/7                phone coverage (2hrs/wk)**                                                                           |       |       |       | x            |       |       |       | 2                 |       | 130        |       | 260                | ** ** | MM       |       |
|                                                                                                                       |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| **Sub-Total**                                                                                                              |       |       |       |         |       |       |       |              |       |       |       | **150**            |       | **PM**   |       |
| **Sub-Total**                                                                                                              |       |       |       |         |       |       |       |              |       |       |       | **175**            |       | **DS**   |       |
| **Sub-Total**                                                                                                              |       |       |       |         |       |       |       |              |       |       |       | **511**            |       | **MM**   |       |
| **Radiology                Review**                                                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| **Provider:                TBD**                                                                                           |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| Database                Development                                                                                        |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| Image                Reciept and Processing                                                                                |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| Image                Review                                                                                                |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| Data                Transfer Files                                                                                         |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| Program                Management                                                                                          |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| **DSMB**                                                                                                                   |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| **Formation                and Management**                                                                                |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| Provide                suitable board members & facilitate (3) meetings by                teleconference               |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| Organize                & Conduct DSMB meetings                                                                        |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| Interact                with sponsor regarding conclusions                                                                 |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| implement                next steps.                                                                                       |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| **Charter                & SOPs**                                                                                      |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| Provide                support/advice for creating DSMB and defining its duties & resp. for                the project |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| **Administration**                                                                                                         |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| Distribute                meeting materials (Send Safety Data)                                                             |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| Prepare                minutes                                                                                             |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| **MD                Participation & Evaluation**                                                                       |       |       |       | N/A          |       |       |       |              |       |       |       |               |       |     |       |
| **Total**                                                                                                                  |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
|                                                                                                                       |       |       |       |         |       |       |       |              |       |       |       |               |       |     |       |
| **Sub-Total**                                                                                                              |       |       |       |         |       |       |       |              |       |       |       | **0**              | ** ** | **PM**   | ** ** |
| **Sub-Total**                                                                                                              | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **0**              | ** ** | **COA**  | ** ** |
| **Sub-Total**                                                                                                              | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **        | ** ** | ** ** | ** ** | **0**              | ** ** | **MM**   |       |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                of Tasks**                                                                          | ** ** | **YM** | ** ** | **Allphase** | ** ** | **ADM** | ** ** | **Task****Hours** | ** ** | **Units** | ** ** | **Total****Hours** | ** ** | **Resp** |   |
|-----------------------------------------------------------------------------------------------------------|------------|--------|------------|--------------|------------|---------|------------|-------------------|------------|-----------|------------|--------------------|------------|----------|--------|
| **Data                Management**                                                                        |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| **Data                Management Plan**                                                                   |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| Project                specific DM standards & SOPs                                                   |       |   |       |         |       | x       |       | 16                |       | 1         |       | 16                 |       | DM       |   |
| Preparation                of Data Management Plan                                                        |       |   |       |         |       | x       |       | 8                 |       | 1         |       | 8                  |       | DM       |   |
| **Database                Design**                                                                        |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| DB                definition                                                                              |       |   |       |         |       | x       |       | 4                 |       | 1         |       | 4                  |       | DM       |   |
| DB                security                                                                                |       |   |       |         |       | x       |       | 4                 |       | 1         |       | 4                  |       | DM       |   |
| CRF                review                                                                                 |       |   |       |         |       | x       |       | 8                 |       | 1         |       | 8                  |       | DM       |   |
| CA3                - Coding data entry screens (17 unique forms, 60 CRF                pages/pt)          |       |   |       |         |       | x       |       | 40                |       | 1         |       | 40                 |       | DM       |   |
| Define                & code edit checks                                                              |       |   |       |         |       | x       |       | 24                |       | 1         |       | 24                 |       | DM       |   |
| Finalize                data entry screens, edit checks, validation                                       |       |   |       |         |       |    |       | 16                |       | 1         |       | 16                 |       | DM       |   |
| **Data                Validation Plan**                                                                   |       |   |       |         |       | x       |       |              |       |      |       |               |       |     |   |
| Initial                programming & query wording                                                    |       |   |       |         |       | x       |       | 8                 |       | 1         |       | 8                  |       | DM       |   |
| Testing                and locking DVP (sign off)                                                         |       |   |       |         |       | x       |       | 4                 |       | 1         |       | 4                  |       | DM       |   |
| Periodic                re-testing                                                                        |       |   |       |         |       | x       |       | 8                 |       | 1         |       | 8                  |       | DM       |   |
| CRF                Completion Guidelines                                                                  |       |   |       | x            |       |    |       |              |       |      |       |               |       | PM       |   |
| CRF                Completion Guidelines review                                                           |       |   |       | x            |       |    |       |              |       |      |       |               |       | CRA      |   |
| Site                training                                                                              |       |   |       | x            |       |    |       |              |       |      |       |               |       | CRA      |   |
| **Data                Entry and Cleaning**                                                                |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |
| Double                Data Entry of all paper CRF data(60                CRF pages/pt)                    |       |   |       |         |       | x       |       | 0.1               |       | 6000      |       | 600                |       | DE       |   |
| Data                Query: Review of listings; query generation (Data Clarification                Forms) |       |   |       |         |       | x       |       | 1                 |       | 100       |       | 100                |       | DM       |   |
| Administration                of DCFs                                                                     |       |   |       | x            |       |    |       | 1                 |       | 100       |       | 100                |       | COA      |   |
| Closing                of DCFs                                                                            |       |   |       |         |       | x       |       | 1                 |       | 100       |       | 100                |       | DE       |   |
| **Medical/Science                Review**                                                                 |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Clinical                Review                                                                            |       |   |       |         |       |    |       | 0.5               |       | 100       |       | 50                 |       | MM       |   |
| **AE/SAE                Database Setup**                                                                  |       | (x)    |       |         |       | x       |       | 16                |       | 1         |       | 16                 |       | DM       |   |
| **SAE                Reconciliation**                                                                     |       |   |       | x            |       |    |       |              |       |      |       |               |       |     |   |
| Reconciliation                based on central SAE DB vs. study DB                                        |       |   |       |         |       |    |       | 16                |       | 1         |       | 16                 |       | DM       |   |
| **Medical                Coding**                                                                         |       |   |       |         |       | x       |       |              |       |      |       |               |       |     |   |
| Coding                AE’s (MedDRA, WHO-ART, COSTART)                                               |       |   |       |         |       |    |       | 0.06              |       | 200       |       | 12                 |       | DM       |   |
| Coding                of Con Meds (WHODRUG)                                                               |       |   |       |         |       |    |       | 0.06              |       | 200       |       | 12                 |       | DM       |   |
| **Data                Validation & Management**                                                       |       |   |       |         |       | x       |       |              |       |      |       |               |       |     |   |
| Periodic                validation of CRF data                                                            |       |   |       |         |       |    |       | 8                 |       | 1         |       | 8                  |       | DM       |   |
| Flexible                query routing                                                                     |       |   |       |         |       |    |       | 0.1               |       | 100       |       | 10                 |       | DM       |   |
| Accommodating                3rd party queries                                                            |       |   |       |         |       |    |       | 0.1               |       | 50        |       | 5                  |       | DM       |   |
| **Central                Lab DB imports**                                                                 |       |   |       | n/a          |       |    |       |              |       |      |       |               |       |     |   |
| Reconcile                Clinical End-Point & CRFDatabase                                             |       |   |       |         |       |    |       |              |       |      |       |               |       |     |   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **List                of Tasks**                                                                                                             | ** ** | **YM**     |       | **Allphase** |       | **ADM**    |       | **Task****Hours**        |       | **Units**  |       | **Total****Hours** |       | **Resp** |       |
|----------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|--------------|------------|------------|------------|--------------------------|------------|------------|------------|--------------------|------------|----------|------------|
| Preparation                of the Interim Analysis Plan                                                                                      |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| Preparation                of the Final Analysis Plan                                                                                        |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| Biostats                & Programming for Interim and Final Analysis                                                                     |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| **DB                lock & audit**                                                                                                       |       |       |       |         |       | x          |       |                     |       |       |       |               |       |     |       |
| Interim                & final DB locks with assoc.documentation                                                                         |       |       |       |         |       |       |       | 24                       |       | 1          |       | 24                 |       | DM       |       |
| 08                documentation & release                                                                                                |       |       |       |         |       |       |       | 8                        |       | 1          |       | 8                  |       | DM       |       |
| DB                transfer in sponsor defined formats (ASCII, SAS, XML as per CDISC                specs)                with detailed docs. |       |       |       |         |       |       |       | 4                        |       | 1          |       | 4                  |       | DM       |       |
| **Randomization                Services**                                                                                                    |       |       |       | x            |       |       |       |                     |       |       |       |               |       |     |       |
| Sample-Size                Justification and Calculation,                                                                                    |       |       |       |         |       |       |       | 6                        |       | 0          |       | 0                  |       | BIO      |       |
| Randomization                Codes - Specification and programming of the randomization                lists                                 |       |       |       |         |       |       |       | 8                        |       | 0          |       | 0                  |       | BIO      |       |
| 24/7                Un-blinding of Patients for 30 months                                                                                    |       |       |       |         |       |       |       | as                needed |       |       |       |               |       | DM       |       |
| One                (1) Study Specific SOP pertaining to the un-blinding of                Patients                                           |       |       |       |         |       |       |       | 3                        |       | 0          |       | 0                  |       | DM       |       |
| **Set-up                (Annual Licenses) and Maintenance**                                                                                  |       |       |       |         |       | x          |       | 3                        |       | 11         |       | 33                 |       | DM       |       |
| **Associated                Project Management**                                                                                             |       |       |       |         |       | x          |       | 2                        |       | 11         |       | 22                 |       | DM       |       |
| **Project                Close-Out & Archiving of database**                                                                             |       |       |       |         |       | x          |       | 24                       |       | 1          |       | 24                 |       | DM       |       |
|                                                                                                                                         |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| **Sub-Total**                                                                                                                                |       |       |       |         |       |       |       |                     |       |       |       | **401**            | ** ** | **DM**   | ** ** |
| **Sub-Total**                                                                                                                                | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **               | ** ** | ** ** | ** ** | **700**            | ** ** | **DE**   | ** ** |
| **Sub-Total**                                                                                                                                | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **               | ** ** | ** ** | ** ** | **100**            | ** ** | **COA**  | ** ** |
| **Sub-Total**                                                                                                                                | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **               | ** ** | ** ** | ** ** | **50**             | ** ** | **MM**   | ** ** |
| **Sub-Total**                                                                                                                                | ** ** | ** ** | ** ** | ** **   | ** ** | ** ** | ** ** | ** **               | ** ** | ** ** | ** ** | **0**              | ** ** | **BIO**  |       |
|                                                                                                                                         |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| **Biostatistical                Services**                                                                                                   |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| Statistical                Analysis Plan (SAP) including mock-up tables, listings and graphs                (optional)                       |       |       |       | x            |       |       |       | 40                       |       | 1          |       | 40                 |       | BIO      |       |
| Statistical                Analyses for all tables, listings and graphs outlined in the                SAP                                   |       |       |       | x            |       |       |       | 152                      |       | 1          |       | 152                |       | BIO      |       |
| Statistical                Report (optional)                                                                                                 |       |       |       | x            |       |       |       | 30                       |       | 1          |       | 30                 |       | BIO      |       |
|                                                                                                                                         |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| Interim                Analysis (Limited)                                                                                                    |       |       |       | x            |       |       |       | 24                       |       | 1          |       | 24                 |       | BIO      |       |
|                                                                                                                                         |       |       |       |         |       |       |       |                     |       |       |       |               |       |     |       |
| **Total**                                                                                                                                    |       |       |       |         |       |       |       |                     |       |       |       | **246**            |       | **BIO**  |       |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**6.      Estimate**

----

| **Service**                                            |       | **Approx.                #****hours** |      | **Hourly                Rate****(CDN)** |   | **TOTALS** |       |
|--------------------------------------------------------|------------|---------------------------------------|-----------|-----------------------------------------|--------|------------|------------|
| **Project                Management (PM)**             |       |                                  |      |                                    |   |       |       |   |   |   |
| Pre-Study                Activities                    |       |                                  | 130       |                                    | $      | [*]        |       | $ | [*] |   |
| Vendors                Selection                       |       |                                  | 32        |                                    | $      | [*]        |       | $ | [*] |   |
| Investigator’s                Meeting            |       |                                  | 85        |                                    | $      | [*]        |       | $ | [*] |   |
| Ethics                                                 |       |                                  | 0         |                                    | $      | [*]        |       | $ | [*] |   |
| Co-Initiation/IMV/COV                                  |       |                                  | 54        |                                    | $      | [*]        |       | $ | [*] |   |
| Ad                hoc meetings                         |       |                                  | 72        |                                    | $      | [*]        |       | $ | [*] |   |
| Safety                - SAE                            |       |                                  | 150       |                                    | $      | [*]        |       | $ | [*] |   |
| Safety                - DSMB                           |       |                                  | 0         |                                    | $      | [*]        |       | $ | [*] |   |
| General                                                |       |                                  | 1287      |                                    | $      | [*]        |       | $ | [*] |   |
| **Sub                Total**                           | ** ** | ** **                            | **1,810** | ** **                              | **$**  | **[*]**    | ** ** | **$** | [*] |   |
| **Regulatory                Affairs (RA)**             |       |                                  |      |                                    |   |       |       |   |   |   |
| Health                Canada Submission                |       |                                  | 0         |                                    | $      | [*]        |       | $ | [*] |   |
| **Sub                Total**                           | ** ** | ** **                            | **0**     | ** **                              | **$**  | [*]        | ** ** | **$** | [*] |   |
| **Clinical                Monitoring (CRA)**           |       |                                  |      |                                    |   |       |       |   |   |   |
| Pre-Study                Activities                    |       |                                  | 24        |                                    | $      | [*]        |       | $ | [*] |   |
| Investigator’s                Meeting            |       |                                  | 102       |                                    | $      | [*]        |       | $ | [*] |   |
| Site                Selection Visits                   |       |                                  | 0         |                                    | $      | [*]        |       | $ | [*] |   |
| Initiation                Visit                        |       |                                  | 209       |                                    | $      | [*]        |       | $ | [*] |   |
| Interim                Monitoring                      |       |                                  | 4580      |                                    | $      | [*]        |       | $ | [*] |   |
| Close-Out                Visit                         |       |                                  | 242       |                                    | $      | [*]        |       | $ | [*] |   |
| **Sub                Total**                           | ** ** | ** **                            | **5157**  | ** **                              | **$**  | [*]        | ** ** | **$** | [*] |   |
| **Clinical                Operations Associate (COA)** |       |                                  |      |                                    |   |       |       |   |   |   |
| Pre-Study                Activities                    |       |                                  | 65        |                                    | $      | [*]        |       | $ | [*] |   |
| Investigator’s                Meeting            |       |                                  | 84        |                                    | $      | [*]        |       | $ | [*] |   |
| DSMB                                                   |       |                                  | 0         |                                    | $      | [*]        |       | $ | [*] |   |
| General                                                |       |                                  | 622       |                                    | $      | [*]        |       | $ | [*] |   |
| Data                Management                         |       |                                  | 100       |                                    | $      | [*]        |       | $ | [*] |   |
| **Sub                Total**                           | ** ** | ** **                            | **871**   | ** **                              | **$**  | [*]        | ** ** | **$** | [*] |   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| **Service**                                                                                     |   | **Approx.                  #****hours** |           | **Hourly                  Rate****(CDN)** |   | **TOTALS** |   |
|-------------------------------------------------------------------------------------------------|--------|-----------------------------------------|----------------|-------------------------------------------|--------|------------|--------|
| **Training                  (ACE)**                                                             |   |                                    |           |                                      |   |       |   |   |   |   |
| Investigator’s                  Meeting                                                   |   |                                    | 0              |                                      | $      | [*]        |   | $ | [*] |   |
| Site                  Training                                                                  |   |                                    | 0              |                                      | $      | [*]        |   | $ | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Quality                  Assurance (QA)**                                                     |   |                                    |           |                                      |   |       |   |   |   |   |
| Vendor                  Audits                                                                  |   |                                    | 52             |                                      | $      | [*]        |   | $ | [*] |   |
| Site                  Audits                                                                    |   |                                    | 160            |                                      | $      | [*]        |   | $ | [*] |   |
| TMF                  Audit                                                                      |   |                                    | 0              |                                      | $      | [*]        |   | $ | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Drug                  Safety – Management**                                        |   |                                    |           |                                      |   |       |   |   |   |   |
| Drug                  Safety                                                                    |   |                                    | 175            |                                      | $      | [*]        |   |   | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Drug                  Safety - Medical**                                                      |   |                                    |           |                                      |   |       |   |   |   |   |
| Investigator’s                  Meeting                                                   |   |                                    | 26             |                                      | $      | [*]        |   | $ | [*] |   |
| Medical                  Monitoring                                                             |   |                                    | 511            |                                      | $      | [*]        |   | $ | [*] |   |
| DSMB                                                                                            |   |                                    | 0              |                                      | $      | [*]        |   | $ | [*] |   |
| Data                  Management                                                                |   |                                    | 50             |                                      | $      | [*]        |   | $ | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Medical                  Writing**                                                            |   |                                    |           |                                      |   |       |   |   |   |   |
| Professional                  Services                                                          |   |                                    | 160            |                                      | $      | [*]        |   | $ | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Data                  Management**                                                            |   |                                    |           |                                      |   |       |   |   |   |   |
| Investigator’s                  Meeting                                                   |   |                                    | 0              |                                      | $      | [*]        |   | $ | [*] |   |
| Double                  Data Entry                                                              |   |                                    | 700            |                                      | $      | [*]        |   | $ | [*] |   |
| Professional                  Services                                                          |   |                                    | 401            |                                      | $      | [*]        |   | $ | [*] |   |
| Site                  Set-up (licenses)                                                         |   |                                    | [*] sites |                                      | $      | [*]        |   | $ | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Biostatistician**                                                                             |   |                                    |           |                                      |   |       |   |   |   |   |
| Data                  Management                                                                |   |                                    | 0              |                                      | $      | [*]        |   | $ | [*] |   |
| Professional                  Services                                                          |   |                                    | 246            |                                      | $      | [*]        |   | $ | [*] |   |
| [Illegible]                                                                                     |   |                                    | [Illegible]    |                                      |   | [*]        |   |   | [*] |   |
| **Radiology                  Review**                                                           |   |                                    |           |                                      |   | [*]        |   | $ | [*] |   |
| Radiology                  Review                                                               |   |                                    |           |                                      |   |       |   |   |   |   |
| **Total                  Project Services                  Fees     ** | **$**  | [*]                                     |           |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**7.      Pass-Through Cost Estimate**

|                                                                                                                                                |   |                                                             |                          | **TOTALS**                   |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------|-------------------------------|------------------------------|--------|
| **Pass-Through                Expenses**                                                                                                            |   | **          ** |                          | **Unit                Cost** |   | **#****Units** |   | **Total                Cost** |   |
| Monitor                Travel Expenses (incl. $0.44/km)                                                                                             |   |                                                             | per                trip       |                         |   | [*] |   |   | 229.00 |   | $ | [*] |   |
| Monitor                Meal Expenses                                                                                                                |   |                                                             | per                day        |                         |   | [*] |   |   | 229.00 |   | $ | [*] |   |
| Monitor                Overnight Expenses (i.e. hotel)                                                                                              |   |                                                             | 30%                           |                         |   | [*] |   |   | 69.00 |   | $ | [*] |   |
| Monitor                Meal Expenses (overnight)                                                                                                    |   |                                                             | per                day        |                         |   | [*] |   |   | 69.00 |   | $ | [*] |   |
| Quality                Assurance / Site Audit Travel                                                                                                |   |                                                             | per                trip       |                         |   | [*] |   |   | 6.00 |   | $ | [*] |   |
| Allphase                & Client Meeting Expenses                                                                                               |   |                                                             | per                person     |                         |   | [*] |   |   | 4.00 |   | $ | [*] |   |
| Miscellaneous                Expenses (consumables and communication costs) = $100 pp /month (active                period): 2CRA, 1COA & 1PM   |   |                                                             | per                month      |                         |   | [*] |   |   | 26.00 |   | $ | [*] |   |
| Miscellaneous                Expenses (consumables and communication costs) = $50 pp /month (follow-up                period): 2CRA, 1COA & 1PM |   |                                                             | per                month      |                         |   | [*] |   |   | 6.50 |   | $ | [*] |   |
| Teleconferences                                                                                                                                     |   |                                                             | per                conf.      |                         |   | [*] |   |   | 69.00 |   | $ | [*] |   |
| Mailing                                                                                                                                             |   |                                                             | per                letter     |                         |   | [*] |   |   | 251.00 |   | $ | [*] |   |
| Courier                                                                                                                                             |   |                                                             | per                package    |                         |   | [*] |   |   | 138.00 |   | $ | [*] |   |
| Newsletters                                                                                                                                         |   |                                                             | per                newsletter |                         |   |   |   |   |   |   |   |   |   |
| Regulatory                Binders                                                                                                                   |   |                                                             | per                site       |                         |   |   |   |   |   |   |   |   |   |
| Study                Reference Binders                                                                                                              |   |                                                             | per                site       |                         |   |   |   |   |   |   |   |   |   |
| Investigator                Grants                                                                                                                  |   |                                                             | per                patient    |                         |   |   |   |   |   |   |   |   |   |
| Ethics                Committee / IRB Fees                                                                                                          |   |                                                             | per                site       |                         |   |   |   |   |   |   |   |   |   |
| Insurance                                                                                                                                           |   |                                                             | per                site       |                         |   |   |   |   |   |   |   |   |   |
| **Sub-Total**                                                                                                                                       |   |                                                             |                          |                         |   |   |   |   |   |   | **$** | [*] |   |
| **Investigator’s                Meeting**                                                                                                     |   |                                                             |                          |                         |   |   |   |   |   |   |   |   |   |
| Investigator                Meeting Airfare - site staff (PI business, CRC economy)                                                                 |   |                                                             | per                person     |                         |   | [*] |   |   | 22 |   | $ | [*] |   |
| Investigator                Meeting Airfare - sponsor staff (all economy)                                                                      |   |                                                             | per                person     |                         |   | [*] |   |   | 9 |   | $ | [*] |   |
| Investigator                Meeting Hotel - site staff(5                star x 3 nights)                                                            |   |                                                             | per                person     |                         |   | [*] |   |   | 22 |   | $ | [*] |   |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

| Investigator                Meeting Hotel - sponsor staff (5 star x 3 nights) |       |       | per                person  |       |       | [*]        |       |       | 9          |       | $          | [*]        |       |
|-------------------------------------------------------------------------------|------------|------------|----------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Transportation                and meals                                       |       |       | per                person  |       |       | [*]        |       |       | 31         |       | $          | [*]        |       |
| **Sub-Total**                                                                 |       |       |                       |       |       |       |       |       |       |       | **$**      | [*]        |       |
|                                                                          |       |       |                       |       |       |       |       |       |       |       |       |       |       |
| **Vendors                (non-affiliated)**                                   |       |       |                       |       |       |       |       |       |       |       |       |       |       |
| Translations                                                                  |       |       | ICF                        |       |       | [*]        |       |       |       |       | $          | [*]        |       |
| Central                Laboratory Service (PK Lab)                            |       |       | per                patient |       |       | [*]        |       |       |       |       |       | [*]        |       |
| IVRS                Vendor                                                    |       |       | N/A                        |       |       |       |       |       |       |       |       |       |       |
| Drug                Distribution Vendor                                       |       |       | N/A                        |       |       |       |       |       |       |       |       |       |       |
| **Sub-Total**                                                                 |       |       |                       |       |       |       |       |       |       |       | **$**      | [*]        |       |
| **Total                Pass-Through Expenses (CDN)**                          | ** ** | ** ** | ** **                 | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | **$**      | [*]        | ** ** |
| ** **                                                                    | ** ** | ** ** | ** **                 | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** |
| **Total                Project (CDN)**                                        | ** ** | ** ** | ** **                 | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | **$**      | [*]        |       |

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**8.      Payment Schedule and Terms**

----

| o | Monthly                labour invoices to be issued by the 15th of the following                month |
|---|-------------------------------------------------------------------------------------------------------|

| o | Expense                invoices to be issued once original receipts have been collected                from                personnel |
|---|--------------------------------------------------------------------------------------------------------------------------------------|

| o | Applicable                taxes on labor will be indicated on                invoice. |
|---|---------------------------------------------------------------------------------------|

| o | Payment                terms are 30 days from receipt of monthly                invoice. |
|---|------------------------------------------------------------------------------------------|

| o | [*]%                per month financing fee may be applied to outstanding balance                owing. |
|---|---------------------------------------------------------------------------------------------------------|

| o | Sponsor                authorization will be obtained if budget exceeds [*]% of                estimate. |
|---|----------------------------------------------------------------------------------------------------------|

| o | Retainer                based payment schedule is also available if                preferred. |
|---|-----------------------------------------------------------------------------------------------|

**9.      Standard Practices**

----

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**10.      Client Signatures**

----

| **YM                BioSciences Inc.** |        |   |       |
|----------------------------------------|-------------|--------|------------|
|                                   |        |   |       |   |
| Signature:                             | [ILLEGIBLE] |   | Signature: | [ILLEGIBLE] |
|                                   |        |   |       |   |

| Date:  | May              16/07 |   | Date:  | 22              May 2007 |
|--------|------------------------|--------|--------|--------------------------|
|   |                   |   |   |                     |

| Name/Title:                                                  | CHAIR              & CEO |                                                                        | Name/Title: | Jeff              Smith/President |
|--------------------------------------------------------------|------------------------------|-----------------------------------------------------------------------------|-------------|-----------------------------------|
|                                                         |                         |                                                                        |        |                              |
| I                have the authority to bind the corporation. |                         | I                have the authority to bind the                corporation. |

*If      the details of this Work Order require further refining and the parties wish      to      initiate work on the project prior to finalizing the Work Order, the Letter      of      Intent of section 11 of this Work Order may be executed.*

----

----

| **MSA#:**                          | YMBO7-MSA-30APR2007-1.0 | **WO                  Version Code:** | YMBO7-WO1-29MAR2007-2.3 |
|------------------------------------|-------------------------|---------------------------------------|-------------------------|
| **Version                  Date:** | 02APR2007               | **Work                  Order #:**    | 01                      |

**11.      Letter of Intent **

----

----

----